FAB — Fusion Antibodies Cashflow Statement
0.000.00%
Last trade - 00:00- £7.71m
- £7.30m
- £1.14m
Annual cashflow statement for Fusion Antibodies, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.697 | -2.9 | -1.2 | -2.6 | -2.23 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | -0.279 | 1.67 | -0.104 | -0.227 | 0.025 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.194 | -0.62 | 0.228 | 0.697 | 0.212 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Cash from Operating Activities | -0.16 | -1.14 | -0.325 | -1.75 | -1.77 |
| Capital Expenditures | -0.109 | -0.365 | -0.258 | -0.114 | -0.002 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.006 | 0.003 | 0.001 | 0.003 | 0.003 |
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.103 | -0.362 | -0.257 | -0.111 | 0.001 |
| Financing Cash Flow Items | -0.012 | -0.018 | -0.009 | -0.004 | -0.005 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.184 | 2.65 | -0.055 | 0.003 | 2.77 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.447 | 1.15 | -0.637 | -1.85 | 1 |